Passive Antibody Protection In The Setting Of Active Cel

目前的候选HIV疫苗可激发相当强大的细胞免疫反应，但只能产生低水平的中和抗体。这种基于CTL的疫苗(例如，基于DNA免疫的疫苗)不能预防感染，但可以对疾病进程产生有益的影响。相比之下，被动注射抗体可以提供完全保护，但注射剂量必须导致血清抗体水平远远高于当前免疫策略所能产生的水平。为了评估CTL能否与抗体结合产生无菌免疫，我们研究了亚适量中和抗体对IL2佐剂DNA免疫诱导的主动免疫动物的影响。使用SHIV-挑战模型，这项研究表明，被动注射抗体可以预防静脉攻击。

Current HIV vaccine candidates elicit reasonably potent cellular immune responses, but only low levels of neutralizing antibodies. Such CTL based vaccines (e.g., those based on DNA immunization) do not prevent infection, but can have a beneficial effect on disease course. In contrast, passively infused antibodies can provide complete protection, but must be administered in doses that result in serum antibody levels much higher than can be generated by current immunization strategies. In order to assess if CTL could combine with antibody to produce sterile immunity, we studied the effect of a suboptimal dose of neutralizing antibodies in animals with active immunity induced by IL2 adjuvanted DNA immunization. Using a SHIV-challenge model, this study has shown that passively infused antibody can protect against an intravenous challenge.